Procedures for reliable estimation of viral fitness from time-series data
暂无分享,去创建一个
Sebastian Bonhoeffer | A. Barbour | S. Bonhoeffer | R. D. de Boer | Rob J De Boer | Andrew D Barbour
[1] E. Domingo,et al. Drastic Fitness Loss in Human Immunodeficiency Virus Type 1 upon Serial Bottleneck Events , 1999, Journal of Virology.
[2] S D Kemp,et al. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.
[3] M A Nowak,et al. Pre-existence and emergence of drug resistance in HIV-1 infection. , 1997, Proceedings. Biological sciences.
[4] R de Boer,et al. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215 , 1997, Journal of virology.
[5] A. Moya,et al. Fitness alteration of foot-and-mouth disease virus mutants: measurement of adaptability of viral quasispecies , 1991, Journal of virology.
[6] M A Nowak,et al. Human immunodeficiency virus drug therapy and virus load , 1997, Journal of virology.
[7] D Norbeck,et al. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.
[8] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[9] D. Richman,et al. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. , 1990, The American journal of medicine.
[10] J. Corbeil,et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.
[11] Wilco Keulen,et al. Estimating Relative Fitness in Viral Competition Experiments , 2000, Journal of Virology.
[12] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[13] J. Martinez-Picado,et al. Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.
[14] S D Kemp,et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.
[15] L. M. Mansky,et al. Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line. , 1996, AIDS research and human retroviruses.
[16] J. Holland,et al. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses , 1991, Journal of virology.
[17] Lin Chao,et al. Fitness of RNA virus decreased by Muller's ratchet , 1990, Nature.
[18] S Bonhoeffer,et al. Production of resistant HIV mutants during antiretroviral therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[19] M A Nowak,et al. Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[20] B. Larder,et al. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy , 1990, The Lancet.
[21] Martin A. Nowak,et al. The frequency of resistant mutant virus before antiviral therapy , 1998, AIDS.
[22] D. Richman,et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.
[23] F. Mammano,et al. Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.
[24] A S Perelson,et al. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase , 1996, Journal of virology.
[25] S. Leal. Genetics and Analysis of Quantitative Traits , 2001 .
[26] Michael Bunce,et al. Evolution and transmission of stable CTL escape mutations in HIV infection , 2001, Nature.
[27] P. Harrigan,et al. Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro , 1998, Journal of Virology.
[28] Sebastian Bonhoeffer,et al. HIV results in the frame , 1995, Nature.
[29] Charles R. M. Bangham,et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.
[30] T. Nagylaki. Introduction to Theoretical Population Genetics , 1992 .
[31] M A Nowak,et al. Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[32] D. Brahams. Human immunodeficiency virus and the law. , 1987, Lancet.
[33] Xiping Wei,et al. Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.
[34] Martin A. Nowak,et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS , 1997, Nature Medicine.
[35] J. Martinez-Picado,et al. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. , 2000, Virology.
[36] John M. Leonard,et al. Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy , 1998, Journal of Virology.
[37] D. Lamarre,et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors , 1997, Journal of virology.
[38] C. Benson,et al. Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection , 1995 .
[39] Sebastian Bonhoeffer,et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.